Login to Your Account

Professor Dr Hasniza Zaman Huri obtained her PhD and Master in Clinical Pharmacy from the National University of Malaysia and B. Pharm (Honours) from the Universiti Malaya. She is the founder Dean of Faculty of Pharmacy, a newly established and the 13th faculty in the University of Malaya since 1 September 2019, and a Professor of Clinical Pharmacy and Pharmacogenomics in the Department of Clinical Pharmacy and Pharmacy Practice. Professor Dr Hasniza and Type 2 Diabetes is inseparable. Her research covers targeted therapy in endocrine diseases, clinical pharmacy, and precision medicine. Professor Dr Hasniza is also an expert in the clinical trial industry. She has published over 80 papers indexed in WOS in her area of expertise. She held various critical administrative posts, including the Manager of Clinical Investigation Centre (CIC) from 2012-2015 and was later appointed as the Director/Head of CIC (2015-2019). CIC, University Malaya Medical Centre is a world-class, reputable and multi-winning clinical trial centre. Under her tenure, CIC has won many accolades at the international level, procured around 590 clinical trials, and worked with 300 pharmaceutical sponsors and CROs worldwide. CIC is recognized as the first Prime Site for Quintiles (now IQVIA) in Asia, the first Strategic Alliance Site for Parexel Inc in Malaysia and Pfizer’s INSPIRE (Investigator Networks, Site Partnerships and Infrastructure for Research Excellence) Site in Malaysia and many more. Previously, Professor Dr Hasniza was also leading the research thrust of UMMC strategic planning. She is also the Honorary Visiting Consultant at CIC and a member of the Drug Control Authority (DCA) Ministry of Health, Malaysia.